Page last updated: 2024-08-26

fulvestrant and B16 Melanoma

fulvestrant has been researched along with B16 Melanoma in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Artham, S; Bae, Y; Baldi, R; Brueckner, O; Byemerwa, J; Chakraborty, B; Chang, CY; Gong, W; Haines, CN; Hanks, BA; Lim, F; Liu, W; McDonnell, DP; Mukherjee, D; Perou, CM; Shepherd, J; Tavares, K; Wardell, SE	1

Other Studies

1 other study(ies) available for fulvestrant and B16 Melanoma

Article	Year
Inhibition of estrogen signaling in myeloid cells increases tumor immunity in melanoma. The Journal of clinical investigation, 2021, 12-01, Volume: 131, Issue:23 Topics: Animals; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Estrogen Receptor alpha; Estrogens; Female; Fulvestrant; Humans; Immune System; Macrophages; Melanoma; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Myeloid Cells; Neoplasm Metastasis; Receptors, Estrogen; RNA, Small Cytoplasmic; Signal Transduction; Skin Neoplasms; Tumor Microenvironment	2021

Article

Year

Inhibition of estrogen signaling in myeloid cells increases tumor immunity in melanoma.

The Journal of clinical investigation, 2021, 12-01, Volume: 131, Issue:23

Topics: Animals; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Estrogen Receptor alpha; Estrogens; Female; Fulvestrant; Humans; Immune System; Macrophages; Melanoma; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Myeloid Cells; Neoplasm Metastasis; Receptors, Estrogen; RNA, Small Cytoplasmic; Signal Transduction; Skin Neoplasms; Tumor Microenvironment

2021